920436

NanoFabTx^™ PEG-PLA drug formulation screening kit

for synthesis of PEGylated nanoparticles

• Synonyme(s) : Microfluidics, NanoFabTx^™ reagent kit, Nanoformulation, Nanoparticle kit, PEG-PLA
• Code UNSPSC : 12161503
• Nomenclature NACRES : NA.23

Propriétés

• Description: Kit components : ; PEGPLA-L-M (919942-500mg); PEGPLA-H-M (919934-500mg); Stabilizer-Nano (907766-5g); PEG-PLA drug formulation screening kit, for synthesis of PEGylated PLA nanoparticles
• Niveau de qualité: 100
• Application(s): advanced drug delivery
• Température de stockage: 2-8°C

Description

Description générale

NanoFabTx^™ PEG-PLA drug formulation screening kit is a nanoformulation kit containing rationally selected PEGylated PLA polymers that have been used widely for controlled drug release of many different types of therapeutic molecules. The kit contains protocols for two different particle synthesis methods:

• A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
• A Microfluidics protocol using commercial platforms or syringe pumps.

The microfluidics protocol uses NanoFabTx^™ device kits (911593), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Application

NanoFabTx^™ PEG-PLA drug formulation screening kit enables users to encapsulate a wide variety of therapeutic drug molecules in specifically sized, biodegradable, PEGylated PLA nanoparticles. By simplifying the chemistry and providing an easy-to-use toolkit with step-by-step instructions, our NanoFabTx^™ nanoformulation screening kit helps researchers achieve reproducible synthesis of drug encapsulating nanoparticles with narrow size dispersity, eliminating the need for lengthy trial-and-error optimization. Suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery, PEG-PLA nanoparticles, made using the NanoFabTx^™ PEG-PLA drug formulation screening kit, are designed for maximizing the encapsulation of hydrophobic drugs to minimize the time and expensive wasted reagents of synthetic optimization.

Caractéristiques et avantages

• Includes tested protocols with step-by-step instructions for nanoprecipitation or microfluidics-based syntheses
• Requires minimal laboratory setup
• Optimized to achieve monodisperse, homogenously shaped, biodegradable, PEGylated PLA nanoparticles in any size between 60 and 100 nm
• Formulated to maximize the encapsulation of hydrophobic drugs
• Includes two different PEGylated PLAs

Informations légales

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Informations sur la sécurité

• Code de la classe de stockage: 10 - Combustible liquids